 Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization. We are delighted to welcome Lori to our board of directors as ORIC embarks on this next phase of its evolution, said Jacob Chacko, M.D., chief executive officer. 